Coverage of a new PCSK9 trial makes bold claims about prevention and risk reduction. But how well do they hold up to scrutiny ...
Patients receiving concomitant PCSK9 inhibitor therapy experienced greater LDL cholesterol reductions, exceeding 50% during ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback